NCT07487376招募中1 期
A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBIO-600 in Overweight or Obese Adult Participants (IBIO-600-CT001).
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- iBio, Inc.
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Assessment of the safety and tolerability of a single dose of IBIO-600
研究概览
简要总结
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
详细描述
The study is a single ascending dose study, with participants monitored for 9 months after administration.
This clinical trial will seek to address the following:
- Which dose of the study drug is most effective.
- How safe the study drug is and how well participants tolerate it.
- How much of the study drug can be found in blood (pharmacokinetics).
- How the study drug affects the body (pharmacodynamics).
- How the body's immune system responds to the study drug (immunogenicity).
- How the body's composition and physical function may change over the course of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 65 years of age
- •In good general health, with no significant medical history
- •BMI between ≥ 27.0 and ≤ 34.90 kg/m2
- •History of self-reported stable body weight (defined as change of no more or less than ± 5%) within 90 days of Screening.
- •Willingness to refrain from any reconstructive and/or cosmetic surgery and/or non-invasive cosmetic procedure that may affect body weight during the study
- •Must be fully ambulatory without any chronic orthopedic diseases or reliance on crutches, walkers, or a wheelchair that may preclude normal activity.
- •Be a nonsmoker/nonvaper and must not have used any nicotine or synthetic type products within 1 month prior to randomization.
- •Must not be pregnant or breastfeeding
- •Woman of childbearing potential (WOCBP) or fertile man agrees to use an acceptable method of contraception from the start of Screening until study completion, or for a minimum of 9 months following the last dose of IP, whichever period is longer.
排除标准
- •An underlying physical or psychological medical conditions that, in the opinion of the PI or medical designee, would make the participant unlikely to comply with the protocol or complete the study per protocol.
- •History or active diagnosis of diabetes (Type 1 or 2).
- •History of insulinoma or recurrent hypoglycemia (≥ 3 episodes in past 3 months).
- •History or presence of clinically significant muscle disease
- •History of or active cardiovascular disease including clinically significant arrhythmias, Class I-IV heart failure, coronary artery disease, thromboembolic event, or pulmonary hypertension.
- •Clinically significant laboratory abnormalities that would preclude participation in the study.
- •History of malignancy, except for non-melanoma skin cancer excised > 2 years ago or cervical intraepithelial neoplasia successfully treated > 5 years prior to randomization.
- •History or presence of any condition associated with significant immunosuppression.
- •History of substance abuse or dependency, or recreational IV drug use within the past 5 years (self-reported).
研究组 & 干预措施
Placebo
Placebo Comparator
Matching placebo
干预措施: Placebo (Drug)
IBIO-600 (Cohort 2)
Experimental
干预措施: IBIO-600 (Drug)
IBIO-600 (Cohort 1)
Experimental
干预措施: IBIO-600 (Drug)
IBIO-600 (Cohort 3)
Experimental
干预措施: IBIO-600 (Drug)
IBIO-600 (Cohort 4)
Experimental
干预措施: IBIO-600 (Drug)
结局指标
主要结局
Assessment of the safety and tolerability of a single dose of IBIO-600
时间窗: From Day 1 through Day 252 (end of study).
Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.
次要结局
- Pharmacokinetics of a single dose of IBIO-600(Baseline up to Week 36)
- Pharmacokinetics of a single dose of IBIO-600(Baseline to the last measurable concentration (AUC0-last))
- Pharmacokinetics of a single dose of IBIO-600(Baseline to infinity (AUC0-inf))
- Pharmacokinetics of a single dose if IBIO-600(Baseline up to Week 36)
- Pharmacokinetics of a single dose of IBIO-600(Baseline through Week 36)
- Pharmacodynamics (PD) of a single dose of IBIO-600(Baseline through Week 36)
- Pharmacodynamics of a single dose of IBIO-600(Baseline up to Week 36)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BNCT07389044IntegerBio80
尚未招募
1 期
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07336472Fortvita Biologics (USA)Inc.360
招募中
2 期
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisAtopic DermatitisNCT07399067Innovent Biologics (Suzhou) Co. Ltd.120
尚未招募
1 期
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic CancerNCT07342725Ruijin Hospital48
Unknown
1/2 期
A study to assess safety, tolerability, and anticancer activity of ISB 1442CTRI/2024/04/065308Ichnos Sciences SA121